Introduction
============

*Raoultella planticola* is a gram-negative rod, aerobic, non-motile, and capsulated bacterium that was first described as *Klebsiella planticola* in 1981 ([@B1],[@B2]). *R. planticola* is included in the Enterobacteriaceae family and has a histidine decarboxylase enzyme that produces histamine from histidine; thus, it can cause histamine fish poisoning ([@B3]). In 2001, it was reclassified as *R. planticola* based on a 16S rRNA and *rpoB* gene analysis ([@B2]). *R. planticola* was initially identified as an environmental bacterium of aquatic, botanic, and soil systems ([@B1],[@B4]). *R. planticola* is generally harmless and rarely causes infection in humans. It colonizes 9-18% of humans, mainly in the urine, feces, and sputum ([@B5],[@B6]). Two cases of infection by *R. planticola* were first reported in 1984 ([@B7]). Since then, cases of *R. planticola* infection have been reported in humans with trauma, malignancy, and gastroenteritis after consuming poorly prepared fish and after invasive medical examinations ([@B5],[@B8]-[@B10]). Although both immunocompetent and immunocompromised hosts can develop *R. planticola* bacteremia, 82.4% of patients are immunocompromised.

We herein report a case of *R. planticola* bacteremia that seemed to be a complication of gallbladder stones and bile duct damage. Because of the rarity of *R. planticola* bacteremia in immunocompetent patients, we screened for possible malignancies and detected early gastric cancer.

Case Report
===========

The patient was an 81-year-old Japanese who presented to our hospital with chills, anorexia, and fatigue that had persisted for several days. He also described intermittent and piercing abdominal pain. He had a history of coronary spastic angina, for which he had been taking diltiazem.

A physical examination at the first visit revealed the following findings: blood pressure, 139/61 mmHg; pulse rate, 55 beats per minute; body temperature, 38.1℃; respiration rate, 24 per minute; and percutaneous oxygen saturation, 95% under room air. The patient\'s consciousness was clear. The abdominal pain had already subsided and he did not have any abdominal tenderness and his system review was unremarkable. Routine laboratory tests were performed because of his advanced age, and due to the presence of fever, and tachypnea. Routine laboratory tests revealed a decreased platelet count (9.1×10^4^/μL) and elevated levels of C-reactive protein (26.3 mg/dL), aspartate transaminase (233 U/L), alanine transaminase (155 U/L), lactate dehydrogenase (477 U/L), γ-glutamyltranspeptidase (127 U/L), creatinine kinase (3,278 U/L), and fibrin degradation product (13.7 μg/dL) ([Table 1](#t001){ref-type="table"}). Abdominal ultrasonography and plain CT of the chest, abdomen, and pelvis showed two stones of 5 mm and 8 mm in diameter in the gallbladder. The patient was admitted to our hospital based on the suspicion of a bacterial infection of unknown nature and rhabdomyolysis. Antibiotic therapy was started empirically with intravenous ampicillin-sulbactam (4.5 g daily) after drawing two sets of blood specimens for bacterial culturing. On the third hospital day, two sets of blood cultures were found to be positive for *R. planticola*. The bacterium was susceptible to ampicillin-sulbactam, cefazolin, ceftriaxone, and levofloxacin, but not ampicillin or amoxicillin ([Table 2](#t002){ref-type="table"}). Although the entry focus of *R. planticola* was unknown, his constitutional symptoms and laboratory data, including his liver function, improved after a total of 14 days of antibiotic therapy (initially with ampicillin-sulbactam, then with ceftriaxone). He also recovered from rhabdomyolysis without aftereffects with fluid replacement alone, and his creatine phosphokinase (CK) level returned to 258 U/L (within the normal range) on the 4th hospital day. He was discharged on the 15th hospital day.

###### 

Laboratory Data on Admission.

  ------------------------ -------------------- -- ---------------- -----------------
  Leukocytes (×10^3^/µL)   7.0 (3.7 - 7.0)         AST (U/L)        233 (13 - 33)
  Neutrophils (%)          85.9 (41.6 - 68.2)      ALT (U/L)        155 (8 - 42)
  Eosinophils (%)          0 (0.1 - 4.2)           LDH (U/L)        477 (119 - 229)
  Basophils (%)            0.4 (0 - 1.0)           γ-GT (U/L)       127 (11 - 58)
  Monocytes (%)            8.4 (4.9 - 9.7)         ALP (U/L)        303 (115 - 359)
  Lymphocytes (%)          5.2 (23.1 - 44.7)       T. Bil (mg/dL)   1.0 (0.2 - 1.2)
  Hemoglobin (g/dL)        14.6 (14.1 - 17.0)      BUN (mg/dL)      34 (8 - 22)
  Platelets (×10^4^/µL)    9.1 (15.9 - 30.0)       Cr (mg/dL)       1.2 (0.6 - 1.1)
  CRP (mg/dL)              26.3 (\<0.2)            FDP (μg/dL)      13.7 (\<5.0)
  CK (U/L)                 3,278 (62 - 287)        PT-INR           1.05
  ------------------------ -------------------- -- ---------------- -----------------

CRP: C-reactive protein, CK: creatine phosphokinase, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, γ-GT: γ-glutamyltranspeptidase, ALP: alkaline phosphatase, T. Bil: total bilirubin, BUN: blood urea nitrogen, Cr: creatinine, FDP: fibrin degradation products, PT-INR: prothrombin time-international normalized ratio

###### 

Susceptibility of *R. planticola* in the Present Case.

  Agent                           Susceptibility   MIC (µg/mL)
  ------------------------------- ---------------- -------------
  Amoxicillin                     R                \>16
  Ampicillin                      R                \>16
  Amoxicillin/clavulanate         S                ≤8
  Ampicillin/sulbactam            S                ≤8
  Piperacillin/tazobactam         S                ≤16
  Cefazolin                       S                ≤2
  Ceftazidime                     S                ≤4
  Cefmetazole                     S                ≤16
  Ceftriaxone                     S                ≤1
  Cefepime                        S                ≤2
  Imipenem                        S                ≤0.5
  Meropenem                       S                ≤0.5
  Gentamicin                      S                ≤4
  Minocycline                     S                ≤4
  Ciprofloxacin                   S                ≤0.06
  Levofloxacin                    S                ≤0.12
  Trimethoprim/sulfamethoxazole   S                ≤40

R: resistant, S: susceptible, MIC: minimum inhibitory concentration

Upper gastrointestinal endoscopy was performed for screening purposes, because most patients with *R. planticola* bacteremia are either immunocompromised or cancer-bearing. An ulcerative lesion was found at the lesser curvature of the upper gastric body ([Figure](#g001){ref-type="fig"}), and a histological examination showed well-differentiated tubular adenocarcinoma. A biopsy of the ulcer showed no sign of *Helicobacter pylori* infection, and the specimen was negative for IgG antibody to *H. pylori*. He was referred to another hospital that specialized in gastroenterology for further examinations and treatment.

![Upper gastrointestinal endoscopy showed an ulcerative lesion in the upper gastric body of the lesser curvature (arrow).](1349-7235-57-1469-g001){#g001}

Discussion
==========

*R. planticola* is a type of commensal bacteria. It is rarely associated with serious infections in humans. In recent years, however, the number of *R. planticola* infections has been increasing. The incidence of *R. planticola* infection might have previously been underestimated due to the difficulty in isolating the bacterium and confusion with other bacteria, including *Klebsiella* spp. ([@B7]).

In the present case, *R. planticola* was detected in the blood, but the focus of bacterial entry was unknown. The abdominal pain, elevated liver enzyme levels, and the presence of gallbladder stones indicated the passage of gallbladder stones through the bile duct, and retrograde infection during this process was a possibility; the gastrointestinal tract is the site of *R. planticola* colonization and no other focus of infection was found in the present case.

We only found 34 cases of *R. planticola* bacteremia in our review of the literature ([Table 3](#t003){ref-type="table"}). The median patient age was 64 years (range: 11 months to 83 years) and the ratio of males was 59.4%. Seven of 34 patients (20.6%) died of *R. planticola* bacteremia. Twenty-four of 34 (70.6%) patients also had a malignancy. The malignancies included hematological malignancies (n=7, 29.2%), biliary tract neoplasms (n=7, 29.2%), pancreatic neoplasms (n=4, 16.7%), and others (n=6, 25.0%). Twenty of 24 patients (83.3%) with malignancies were treated with chemotherapy or stem cell transplantation ([@B11]-[@B15]) before the development of bacteremia. Thus, an immunocompromised state - due to either a malignancy itself or the associated chemotherapy - appears to be associated with the development of *R. planticola* bacteremia. Eight of 34 (23.5%) patients received invasive medical procedures such as endoscopic retrograde cholangiopancreatography, central venous catheterization, and cardiovascular surgical procedures ([@B6],[@B7],[@B15]-[@B17]). It is noteworthy that 14 of 34 (41.2%) patients had a malignancy or a history of invasive medical procedures to the hepatobiliary system or pancreas, indicating that the hepatobiliary system or pancreas is one of the foci of *R. planticola* bacteremia.

###### 

Reported Cases of *R. planticola* Bacteremia.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference   Age / Sex        Comorbidity                                                  Invasive\                  Antibiotics                                                          Outcome
                                                                                            procedures                                                                                      
  ----------- ---------------- ------------------------------------------------------------ -------------------------- -------------------------------------------------------------------- -----------
  7           69 / F           Mitral stenosis                                              Mitral valve replacement   Tobramycin and cefotaxime                                            Recovered

  6           57 / N/A         N/A                                                          Post-CABG                  Ceftriaxone                                                          Recovered

  11          83 / F           N/A                                                          N/A                        Moxifloxacin, ceftriaxone, azithromycin, and meropenem               Died

  11          64 / M\*         B cell lymphoblastic lymphoma                                N/A                        Doxycycline                                                          Died

  16          65 / M           Advanced apocrine adenocarcinoma                             ERCP                       Cefoperazone / sulbactam, meropenem, and piperacillin / tazobactam   Recovered

  17          59 / M           Pancreatic carcinoma                                         ERCP                       Piperacillin / tazobactam                                            Recovered

  24          75 / M           Pancreatic carcinoma                                         N/A                        Cefotaxime and metronidazole                                         Died

  10          63 / M           Hypercholesterolemia, BPH, and Posterior pituitary adenoma   N/A                        Piperacillin / tazobactam and Cefotaxime                             Recovered

  12          70 / M\*         Pancreatic adenocarcinoma, COPD, and Bronchiectasis          N/A                        Ciprofloxacin and metronidazole                                      Recovered

  13          57 / M\*         Non-small-cell lung cancer with multiorgan metastasis        N/A                        Levofloxacin, gentamicin, and ceftazidime                            Recovered

  14          56 / F\*         Non-small-cell lung cancer with liver metastases             N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          51 / F\*         Multiple myeloma                                             N/A                        Ciprofloxacin                                                        Recovered

  15          69 / F\*         Cervical cancer                                              N/A                        Ceftriaxone and ciprofloxacin                                        Recovered

  15          64 / M\*         Cholangiocarcinoma                                           N/A                        Piperacillin / tazobactam                                            Recovered

  15          64 / M\*         Acute myeloid leukemia                                       Central line               Cefepime                                                             Recovered

  15          59 / M           AMI, ROSC after cardiac arrest                               Central line               Vancomycin and imipenem                                              Died

  15          66 / F\*         Gallbladder adenocarcinoma                                   N/A                        Piperacillin / tazobactam                                            Recovered

  15          81 / M\*         Cholangiocarcinoma                                           N/A                        Piperacillin / tazobactam and levofloxacin                           Recovered

  15          72 / M           Hepatocellular carcinoma                                     N/A                        No treatment                                                         Died

  15          59 / M\*         Multiple myeloma                                             N/A                        Cefepime and metronidazole                                           Recovered

  15          54 / F\*         Cervical cancer                                              N/A                        Meropenem and tobramycin                                             Died

  15          69 / F           Diabetes mellitus                                            N/A                        Ciprofloxacin                                                        Recovered

  15          60 / F\*         Diffuse large B cell lymphoma                                N/A                        Vancomycin and cefepime                                              Recovered

  15          75 / F\*         Gallbladder adenocarcinoma                                   N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          78 / F\*         Cholangiocarcinoma                                           N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          53 / F\*         Gallbladder adenocarcinoma                                   N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          65 / M\*         Pancreatic adenocarcinoma                                    N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          69 / F           Nonspecific                                                  N/A                        Ceftriaxone and metronidazole                                        Recovered

  15          18 / M\*         B cell lymphoblastic lymphoma                                Central line               Cefepime and teicoplanin                                             Recovered

  15          75 / M\*         Cholangiocarcinoma                                           N/A                        Piperacillin / tazobactam                                            Recovered

  15          21 / M\*         Acute myeloid leukemia                                       Central line               Meropenem and cefepime                                               Recovered

  25          11 month / N/A   N/A                                                          N/A                        N/A                                                                  N/A

  9           52 / M           Chronic pancreatitis, HT, and CRD                            N/A                        N/A                                                                  Died

  26          62 / M           DM, HT, and BPH                                              N/A                        Piperacillin / tazobactam, ceftriaxone, and ciprofloxacin            Recovered

  Our case    81 / M           Coronary spastic angina and gastric carcinoma                None                       Ampicillin / sulbactam and ceftriaxone                               Recovered
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* The patient was treated with chemotherapy or stem cell transplantation.

M: male, F: female, N/A: not available, CABG: coronary artery bypass grafting, ERCP: endoscopic retrograde cholangiopancreatography, BPH: benign prostatic hypertrophy, COPD: chronic obstructive pulmonary disease, AMI: acute myocardial infarction, ROSC: return of spontaneous circulation, HT: hypertension, CRD: chronic renal disease, DM: diabetes mellitus

*R. planticola* is usually susceptible to most antibiotics except ampicillin. However, recently, *R. planticola* with resistance to carbapenems or with extended spectrum β lactamase has been reported ([@B18],[@B19]). In two of the cases in [Table 3](#t003){ref-type="table"}, *R. planticola* was resistant to carbapenems ([@B11],[@B13]). In one of these two cases, *R. planticola* was susceptible to gentamicin, levofloxacin, and tetracycline ([@B11]); in the other, it was susceptible to fluoroquinolone, aminoglycoside, and colistin ([@B13]). Based on these findings, aminoglycoside or fluoroquinolone may appropriate choices of antibiotics for carbapenem-resistant *R. planticola*.

Some bacteria are considered to be related to malignancy. For example, *Streptococcus gallolyticus* subsp. gallolyticus (SGG), which was formerly named *Streptococcus bovis* biotype I, and *Clostridium septicum* bacteremia are associated with colorectal malignancy ([@B20]). In addition to colonizing colorectal neoplasms and invading the blood from the damaged mucosa, SGG may also actually cause colorectal malignancies. On the other hand, *C. septicum* bacteremia occurs through mucosal damage caused by carcinoma ([@B21]-[@B23]). Although the cause-and-effect relationship between *R. planticola* bacteremia and malignancy is unknown, the literature suggests that *R. planticola* bacteremia occurs in patients who are immunocompromised as a result of malignancy. We need to accumulate additional cases of *R. planticola* bacteremia to clarify the relationship between *R. planticola* and early-stage cancer.

It is intriguing to consider the cause-and-effect relationship between *R. planticola* bacteremia and early gastric cancer in the present case. Although the association remains elusive, the fact that most patients with *R. planticola* bacteremia are immunocompromised or cancer-bearing led us to screen for malignancies; the patient happened to have gastric cancer without any symptoms. Thus, when we encounter such patients, it may be worthwhile to screen for malignancies.
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